Marine Actinomycetes as a Resource for Anticancer Natural Products

海洋放线菌作为抗癌天然产品的资源

• 批准号: 8125064
• 负责人: JOHN B MACMILLAN
• 金额: $ 31.9万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-08-10 至 2015-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8125064
• 关键词: Actinobacteria class; Analytical Chemistry; Antineoplastic Agents; Apoptosis; Bacteria; Biochemical; Biochemistry; Biological; Biological Assay; Biological Factors; Biomedical Research; Cancer Biology; Cell Line; Cells; Cellular biology; Chemicals; Chemistry; Chromatography; Collaborations; Collection; Colon Carcinoma; Complex Mixtures; Cytotoxic agent; DNA Methyltransferase; DNA Modification Methylases; Development; Discipline; Environment; Environmental Risk Factor; Epigenetic Process; Evaluation; Exhibits; FDA approved; Fermentation; Foundations; Generations; Germination; Goals; Habitats; Health; Histone Deacetylase; Human; Lead; Libraries; Malignant Neoplasms; Marines; Mass Spectrum Analysis; Methodology; Microbiology; Molecular; Natural Products Chemistry; Necrosis; Pathway interactions; Pharmaceutical Preparations; Pharmacology; Plant Resins; Property; Research; Resources; Screening procedure; Signal Pathway; Signal Transduction; Signal Transduction Pathway; Solid; Specificity; Structure; Techniques; Technology; Therapeutic; Translational Research; Tumor Cell Line; X-Ray Crystallography; analytical method; anticancer research; base; cancer therapy; cellular targeting; cytotoxic; cytotoxicity; drug discovery; high throughput screening; insight; microbial; microorganism; novel; oncology; programs; public health relevance; quorum sensing; rapid technique; reversed phase chromatography; small molecule; tool; tumor

DESCRIPTION (provided by applicant): Fermentation derived natural products from actinomycetes and other bacteria have been an important component of drug discovery inspiring 50% of clinically approved drugs and proven to be invaluable tools in cancer research. Natural products often exert their effects potently and exhibit high specificity - making them useful to probe signaling pathways related to cancer. As such, a continued effort to identify new natural products with potent biological activity relevant to human cancers is an important endeavor. The goal of this project is to identify new natural products that can be lead structures for the development of novel cancer therapeutics or biochemical probes. A multi-faceted approach that combines microbiology, natural products chemistry and collaboration with experts in cancer biology will be used to accomplish this goal. Specifically, we propose to develop new empirical and biochemical techniques to culture actinomycetes from marine habitats, by taking advantage of environmental factors such as pH, pO2 and chemical signaling. As it is widely believed that only a small percentage of bacteria are culturable, new techniques to isolate secondary metabolite producing bacteria are necessary. The collection of marine bacteria will serve as the foundation to build a natural product fraction library for biological screening efforts. We will use a combination of biochemical target-based assays, cell-based phenotypic assays and selective cytotoxicity studies to identify molecules that interact with signal transduction pathways (eg. apoptosis, necrosis, Wnt/?-catenin, HIF) and modulate epigenetic factors such as DNA methyltransferase and histone deacetylase. An example of a specific biological target, we will utilize a cell-based assay to discover molecules that interact specifically in the Wnt pathway using a Wnt responsive cell line, which is important in large number of cancers (most notably up to 90% of colon cancer). To accommodate the chemical evaluation of active hits in the large number of bioassays proposed, we will develop analytical chemistry techniques based on LC-SPE-NMR technology for rapid quantitative and qualitative analysis. Finally, we will use traditional natural products chemistry techniques to characterize new secondary metabolites that we identify in our biological screening. PUBLIC HEALTH RELEVANCE: A large fraction of FDA approved anticancer drugs are based upon natural products derived from microbial resources. This research will investigate new methodologies to identify new natural products from underdeveloped resources for the treatment of cancer. Our research combines expertise in natural products along with experts in cancer biology.

描述（由申请人提供）：放线菌和其他细菌发酵衍生的天然产物一直是药物发现的重要组成部分，激发了50%的临床批准药物，并被证明是癌症研究中的宝贵工具。天然产物通常发挥其有效作用，并表现出高度特异性-使其可用于探测与癌症相关的信号通路。因此，继续努力鉴定具有与人类癌症相关的有效生物活性的新天然产物是一项重要的奋进。该项目的目标是鉴定新的天然产物，这些产物可以成为开发新型癌症治疗剂或生化探针的先导结构。一个多方面的方法，结合微生物学，天然产物化学和合作与癌症生物学专家将被用来实现这一目标。具体而言，我们建议开发新的经验和生物化学技术培养放线菌从海洋栖息地，利用环境因素，如pH值，pO 2和化学信号。由于人们普遍认为只有一小部分细菌是可培养的，因此需要新的技术来分离产生次级代谢产物的细菌。海洋细菌的收集将作为建立生物筛选工作的天然产物组分库的基础。我们将使用基于生化靶点的测定、基于细胞的表型测定和选择性细胞毒性研究的组合来鉴定与信号转导途径相互作用的分子（例如，凋亡、坏死、Wnt/？-连环蛋白，HIF）和调节表观遗传因子如DNA甲基转移酶和组蛋白脱乙酰酶。作为特定生物靶标的一个例子，我们将利用基于细胞的测定来发现使用Wnt应答细胞系在Wnt途径中特异性相互作用的分子，这在大量癌症中很重要（最值得注意的是高达90%的结肠癌）。为了适应在大量的生物测定提出的活性命中的化学评价，我们将开发基于LC-SPE-NMR技术的分析化学技术，用于快速定量和定性分析。最后，我们将使用传统的天然产物化学技术来表征我们在生物筛选中识别的新次级代谢产物。 公共卫生相关性：FDA批准的抗癌药物中有很大一部分是基于来自微生物资源的天然产物。这项研究将探讨新的方法，以确定新的天然产品，从欠发达的资源，用于治疗癌症。我们的研究结合了天然产品的专业知识沿着与癌症生物学专家。